FutFormProject reference: 691128
Funded under :
Future Formulations: Developing Future Pharmaceuticals Through Advanced Analysis and Intersectoral Exchange
Total cost:EUR 414 000
EU contribution:EUR 414 000
Coordinated in:United Kingdom
Call for proposal:H2020-MSCA-RISE-2015See other projects for this call
Funding scheme:MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)
The estimated cost of getting a new medicine to market is now in excess of $2.6 billion, with an additional $300 million (approx.) typically being directed towards post market approval research and development activities (including testing of new indications, new formulations and new dosage strengths and regimens) (Nature Reviews Drug Discovery 13, 877 (2014)). These costs have increased >145% since 2003, and reflect an increasingly complex process in which there remains a high chance of failure in the expensive later phases of development.
With the aim of reducing the times and costs associated with medicine development, increasing attention has focused on the development of approaches to better predict and/or optimize the behaviour of actives and their formulations at an earlier stage of development. Recent research within the School of Pharmacy (University of Nottingham (UoN)) has focussed on the application of advanced surface analytical and biophysical tools to address this need. This proposal will build on this activity via an intersectoral researcher exchange program focussed on supporting future pharmaceutical formulations development.
The principal objective of FutForm is to translate the advanced analytical approaches developed within UoN, so that they become embedded into industrial practice for the development of future pharmaceutical processes and therapies. This will be achieved through a collaborative programme of researcher secondments with three small-medium enterprise (SME) companies, each with early stage innovative technologies in areas of importance to the future pharmaceutical industry, namely; enzyme formulations for improved cell isolation (Abiel s.r.l; Italy), nanoparticle platform formulations for oral and topical drug delivery (Inovapotek, Pharmaceutical Research and Development Lda; Portugal) and hydrogel formulations for cell-delivery (Hy2Care b.v.; Netherlands).
EU contribution: EUR 297 000
NG7 2RD NOTTINGHAM
EU contribution: EUR 36 000
UPTEC - RUA ALFREDO ALLEN 455/461
EU contribution: EUR 54 000
DRIENERLOLAAN 5 MIRA ZUIDHORST KAMER 127
7522 NB ENSCHEDE
EU contribution: EUR 27 000
VIA DEL MARE 3
91021 CAMPOBELLO DI MAZARA